Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission

Minimal residual disease (MRD) before myeloablative hematopoietic cell transplantation (HCT) is associated with adverse outcome in acute myeloid leukemia (AML) in first complete remission (CR1). To compare this association with that for patients in second complete remission (CR2) and to examine the...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Walter, Roland B., Buckley, Sarah A., Pagel, John M., Wood, Brent L., Storer, Barry E., Sandmaier, Brenda M., Fang, Min, Gyurkocza, Boglarka, Delaney, Colleen, Radich, Jerald P., Estey, Elihu H., Appelbaum, Frederick R.
Formato: Artigo
Idioma:Inglês
Publicado: American Society of Hematology 2013
Assuntos:
Transplantation
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3765060/
https://ncbi.nlm.nih.gov/pubmed/23847197
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2013-06-506725
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares